The Lancet Study: Russia’s Potential Covid-19 Coronavirus Vaccine Shows Promise

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part #COVID19 vaccine (2/8) pic.twitter.com/fcYqgpjfsl

— The Lancet (@TheLancet) September 4, 2020

CNBC: Russia’s potential coronavirus vaccine shows ‘no serious adverse’ effects and creates antibody response: The Lancet study

* Clinical trials of Russia’s potential vaccine involved 76 healthy volunteers, aged 18 to 60.
* “Large, long-term trials including a placebo comparison, and further monitoring are needed,” the study’s authors said.
* The chief of Russian sovereign wealth fund RDIF, which is backing the vaccine, said the country was “on track” to provide exports of the vaccine by November.

Early results from trials of Russia’s potential coronavirus vaccine show no major negative side effects, a study published in the peer-reviewed medical journal The Lancet revealed Friday.

Doctors involved in the trials conducted “two open, non-randomised phase 1/2 studies at two hospitals in Russia,” on 76 healthy volunteers aged 18 to 60, the Lancet article said. It added that the vaccine formulations tested were “safe and well tolerated.”

“The two 42-day trials – including 38 healthy adults each – did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” the study’s authors wrote.

Read more ....

Update #1: Russia's Covid-19 vaccine generated an immune response, study says (CNN)
Update #2: Russia Vaccine Passes Early Trial Test – The Lancet (Moscow Times/AFP)

WNU Editor: This vaccine trial only involved 76 healthy volunteers. That is a small sample size. They will need to test it on thousands, and apparently they are getting ready to test this on 40,000 volunteers. But if these results are true, this then looks promising. The Lancet report is here .... Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (The Lancet).